Joint Disease: What the Research Says
Evidence from 30 peer-reviewed studies
1 RCT
4 Cohort Study
3 Case Report
20 Expert Opinion
2 Thesis
What Professionals Should Know
- •IA hyaluronan (NASHA) appears safe for joint injection with good clinical tolerance, despite triggering a mild synovial inflammatory response on biomarker analysis
- •The lack of significant biomarker differences between treated and control groups suggests caution in assuming superiority of NASHA over placebo for modifying joint pathology in the short term
- •Monitor for transient synovial reaction after IA NASHA injection, though this does not appear to cause clinical problems in practice
- •IR spectroscopy of synovial fluid offers a potential non-invasive screening tool for early detection of OA that is more economical and accessible than current diagnostic methods
- •This technique could enable earlier intervention in OA cases by identifying biochemical changes before radiographic or clinical signs become apparent
- •Further validation in clinical field settings is needed before implementation, but this represents a promising advancement for routine OA screening in performance horses
- •Clodronate disposition data now available to guide dosing decisions for joint disease in horses, with documented safety monitoring parameters for renal function
- •Synovial fluid penetration confirmed, supporting use in osteoarthritis and degenerative joint conditions
- •Monitoring urinary excretion and renal indices recommended when using clodronate in clinical practice
- •CD-RAP measurement in synovial fluid shows promise as a biomarker for detecting early cartilage changes and joint disease progression in individual horses when monitored longitudinally
- •Since disease significantly alters CD-RAP levels, this test could potentially help differentiate between healthy and diseased joints earlier than traditional clinical or imaging methods
- •The assay's moderate to large variation means results are most reliable for tracking changes within the same horse over time rather than for absolute comparisons between horses
- •When using synovial fluid biomarkers to diagnose early osteoarthritis, standardize the timing and frequency of joint taps and exercise history to avoid misinterpretation of results
- •Multiple arthrocentesis procedures and recent exercise can alter biomarker concentrations, so document these variables when collecting and comparing synovial samples
- •Baseline biomarker values in healthy joints are influenced by sampling technique and activity level—establish consistent pre-sampling protocols for reliable clinical comparison
- •Be alert to improved respiratory performance following intra-articular corticosteroid injections, as this may mask underlying asthma and delay proper diagnosis
- •Consider respiratory status separately from joint treatment response when evaluating equine athletes receiving intra-articular corticosteroids
- •Document baseline lung function and monitor respiratory signs independently in horses receiving joint corticosteroid therapy
- •Administering firocoxib to horses at the time of ACS preparation will not result in positive plasma drug tests following intra-articular joint injection, providing reassurance regarding inadvertent contamination
- •Practitioners can safely prepare ACS from horses receiving therapeutic firocoxib without concern for subsequent doping violations in performance horses
- •The rapid clearance of firocoxib (undetectable within 14 days) and minimal systemic absorption from intra-articular ACS injection suggests minimal risk of drug test violations when using this orthobiologic therapy
- •Synovial fluid and membrane samples collected routinely during arthroscopy can serve as accessible sources for obtaining equine MSCs without additional tissue harvest
- •These MSCs show promise as candidates for autologous cell therapy in joint regeneration, offering a less invasive collection method than bone marrow or adipose tissue
- •Characterization protocols established here provide a framework for validating MSC quality from synovial sources in clinical applications
- •Standing CT technology now enables non-invasive early detection of subchondral bone changes before clinical lameness appears, allowing for preventive intervention strategies.
- •SCB abnormalities are emerging as valuable biomarkers for predicting OA and fracture risk, suggesting monitoring these changes could guide management decisions for at-risk horses.
- •Combining advanced imaging with AI tools promises to move from reactive treatment toward predictive medicine, potentially extending athletic careers and improving long-term soundness outcomes.
- •Current biologic therapy use varies significantly among board-certified equine practitioners, suggesting ongoing debate about optimal treatment selection
- •Understanding specialist preferences and practices can help inform clinical decisions when considering biologic therapies for musculoskeletal injuries
- •This survey provides insight into which biologic approaches are most commonly adopted in real-world equine practice settings
- •Gene therapy represents an emerging experimental treatment option for equine OA that may progress to clinical use; monitor literature for clinical trial opportunities
- •Current evidence is still preclinical/experimental—gene therapy is not yet standard clinical practice, so continue conventional lameness management strategies
- •Understanding that OA involves multiple joint tissues (not just cartilage) supports multimodal therapeutic approaches beyond single-agent interventions
- •NSAIDs remain a cornerstone of orthopaedic management in horses; choice between selective and non-selective agents should be based on individual case needs and contraindications
- •Understanding NSAID effects on both normal and inflamed tissues helps optimize treatment protocols and minimize adverse effects in your patients
- •Stay informed about emerging anti-inflammatory strategies as new options may complement or enhance traditional NSAID therapy for orthopaedic cases
- •UC-II supplementation may offer a more effective alternative to traditional joint supplements (glucosamine/chondroitin) at lower doses for companion animals with joint disease
- •Consider UC-II as a therapeutic option for osteoarthritis management in large breed dogs and horses
- •Further research is needed to establish optimal dosing protocols and clinical outcomes in equine patients
- •HA is an evidence-based therapeutic option for managing joint disease in horses; understanding that molecular weight matters will help you select appropriate products for your patients
- •HA works through multiple biological pathways to reduce arthritic changes, not just as a lubricant—this supports its use early in joint disease before significant cartilage loss occurs
- •HA's broad therapeutic applications beyond joints (wound healing, ophthalmology, dermatology) may offer additional clinical opportunities in equine practice
- •Cell-based therapy products vary widely in composition and effectiveness — understand the specific preparation method and source material (adipose, bone marrow, or whole blood derived) of any product you consider using
- •Treatment outcomes depend heavily on case selection (disease stage and type of injury); early-stage OA or soft tissue injuries may respond differently than advanced joint disease
- •Until regulatory standards are established, critically evaluate the evidence quality and manufacturing consistency of any cell-based therapy product before clinical application
- •Subchondral bone changes often precede cartilage damage in osteoarthritis development—early detection via advanced imaging (CT/MRI) may enable earlier intervention before irreversible joint changes occur
- •Managing repetitive loading stresses through appropriate conditioning, farrier care, and exercise modification is critical for preventing subchondral bone pathology rather than treating established disease
- •Current treatment options remain limited by incomplete understanding of subchondral bone mechanics; focus should be on prevention and early detection rather than expecting curative therapies
- •CT and MRI should be considered when early cartilage damage is suspected but conventional radiographs appear normal, particularly in high-value performance horses
- •These advanced imaging modalities enable more precise characterization of joint pathology, potentially improving treatment decisions and prognosis estimates
- •Further research is needed to establish standardized protocols and clinical thresholds for equine cartilage evaluation using CT and MRI techniques
- •SF-derived MSCs from horses and sheep can be reliably isolated and characterized for potential joint disease therapies, with quantum dot labelling enabling effective cell tracking in research and clinical applications
- •Species-specific differentiation patterns should be considered when selecting MSC sources for particular therapeutic goals—equine cells favor adipogenesis while ovine cells favor chondrogenesis
- •Standardized labelling protocols using quantum dots at 2-10 nmol/L provide efficient, trackable cell preparations for evaluating MSC behavior in joint environments
- •Several experimental cell-based cartilage repair techniques are available for horses with articular surface damage, though none are standard treatments—discuss emerging options like stem cell therapy and scaffold-based chondrocyte implantation with your veterinarian for individual cases.
- •Preventive management and early intervention are critical since cartilage has poor intrinsic healing and joint disease remains a major cause of athletic retirement.
- •Consult with veterinary specialists experienced in regenerative medicine techniques as these approaches vary significantly in availability, efficacy, and cost.
- •Understanding the link between coagulation activation and joint inflammation may inform future therapeutic targets for managing joint disease in horses
- •Anti-inflammatory and anticoagulant strategies may have complementary roles in treating acute synovitis, though clinical validation is needed
- •The temporal expression patterns suggest early intervention after joint injury may be critical to prevent cascade amplification of inflammation
- •When evaluating research on OA treatments and diagnostics, consider which animal model was used—findings from rodent models may not directly translate to equine OA due to differences in joint mechanics and disease progression
- •Large animal models (sheep, goat, horse) more closely replicate human and equine OA pathology than small rodents, making them more clinically relevant for pre-clinical testing of joint therapies
- •Research into early OA detection and disease-modifying treatments is still developing; current clinical tools are limited, so staying informed about emerging diagnostic methods from animal studies is important
- •Hoof-strike orientation significantly influences impact loading patterns; heel-first impacts generate the highest accelerations and may increase injury risk in predisposed horses
- •Farriers should consider hoof balance and trim to optimize strike patterns, as the distal limb structures attenuate but do not fully dissipate impact energy
- •Adding weight to the distal limb does not reduce impact shock transmission, so ballast-based interventions are unlikely to protect against impact-related injury
- •Hoof angle alone does not significantly alter impact loading distribution in the MCP joint, suggesting joint disease risk is multifactorial beyond farriery adjustments
- •The medial condyle dorsal surface bears the highest impact stress and may warrant targeted protective or rehabilitative strategies in horses with MCP joint pathology
- •Impact loading creates fundamentally different joint contact patterns than static stance, indicating that gait analysis and impact management may be more important than hoof angle for joint health
- •Understanding equine OA pathogenesis and progression can directly improve management and treatment strategies for arthritic horses in practice.
- •Research findings from equine OA studies are directly translatable to horses with clinical joint disease, offering evidence-based treatment options.
- •Early intervention windows identified in equine models suggest opportunities to prevent or slow OA progression in at-risk horses before clinical signs become severe.
- •Understanding the comparative strengths of CT, CECT, and standing LFMRI helps practitioners select the most appropriate imaging modality for specific foot pathology types
- •Standing LFMRI offers a non-invasive alternative to traditional imaging without requiring general anesthesia, but clinicians need to know when each modality has superior diagnostic capability
- •Knowledge of imaging limitations prevents missed diagnoses and guides whether additional or alternative imaging is warranted in equine foot lameness cases
- •Synovial fluid analysis for chondroitin sulphate can identify joint pathology in horses without clinical signs, enabling early intervention before symptomatic disease develops
- •Asymptomatic OCD with elevated synovial fluid markers may warrant arthroscopic intervention to remove osteochondral fragments and prevent progression to symptomatic disease
- •Synovial fluid sampling and analysis offers a non-invasive diagnostic tool beyond clinical examination to assess true joint health status in at-risk horses
- •Combined glucosamine and chondroitin supplements appear safe for equine joint health and may help prevent cartilage degradation associated with osteoarthritis
- •Higher dosages of the combination product showed better results than lower dosages or individual components, informing clinical dosing recommendations
- •This research provides mechanistic support for the use of these nutraceuticals in equine joint supplements, though clinical efficacy in laminitis or performance horses requires further investigation
- •Arthroscopic findings in early cartilage disease (minor damage) should be interpreted conservatively as visible damage is likely worse than arthroscopy suggests
- •In severely damaged joints, arthroscopic appearance may overstate the problem; consider that lesions visible in the dorsal pouch may not reflect damage elsewhere in the joint
- •Arthroscopy is most reliable for moderately severe lesions; for early or advanced disease, consider complementary imaging or clinical correlation
- •Understanding how joint loading affects cartilage cell metabolism may help explain early degenerative changes in working horses and inform management strategies
- •Mechanical stress on articular cartilage triggers biochemical responses that could be targeted therapeutically to prevent or slow osteoarthritis development
- •This foundational research supports the importance of appropriate exercise and loading patterns in cartilage health maintenance
- •In vitro findings suggest corticosteroid joint injections may not fully protect cartilage from inflammatory damage, challenging assumptions about protective efficacy and warranting careful clinical evaluation of their true benefit
- •Dosage reduction of corticosteroid intra-articular injections does not appear to reduce cartilage metabolic harm in this model, suggesting current clinical dosing practices may not be optimizable through simple dose reduction
- •Results diverge from in vivo studies, highlighting important limitations of in vitro cartilage models and emphasizing the need for continued clinical outcome research before changing current injection protocols
Key Research Findings
Cartilage-derived biomarker CS846 decreased in the NASHA treatment group but showed no statistically significant difference compared to control
White blood cell count in synovial fluid increased significantly after intra-articular NASHA injection, suggesting a mild inflammatory response
No statistically significant treatment effects were observed for any biomarkers between treatment groups
Intra-articular NASHA was well tolerated with no clinical adverse effects observed
IR spectroscopy of synovial fluid achieved 80% accuracy in distinguishing OA joints from control joints
Classification accuracy by sampling day reached 87% for temporal differentiation
Paired comparison of OA versus OA control joints showed 75% accuracy, while OA versus Sham comparison showed 70% accuracy
Synovial fluid IR spectroscopy can detect early biochemical changes associated with traumatically induced OA within 63 days post-induction
Study describes pharmacokinetics of clodronate disodium in plasma, synovial fluid, and urine following systemic administration in horses
First peer-reviewed report evaluating renal health indices and urinary excretion patterns in conjunction with clodronate administration
Clodronate achieves measurable concentrations in synovial fluid, relevant for intra-articular disease management
CD-RAP was detected in healthy equine synovial fluid at concentrations of 8.2-52 ng/ml with moderate to large assay variation
CD-RAP concentrations were significantly lower 12 hours after lipopolysaccharide injection compared to saline and remained suppressed through 144 hours
The human CD-RAP ELISA assay is suitable for longitudinal monitoring in individual horses despite cross-species application
CD-RAP appears to be a marker of cartilage synthesis and regeneration in horses, similar to findings in humans
Evidence Base
Changes in biomarkers in equine synovial fluid two weeks after intra-articular hyaluronan treatment: a randomised double-blind clinical trial.
Niemelä Tytti M, Tulamo Riitta-Mari, Aaltonen Kaisa et al. (2018) — BMC veterinary research
RCT
Infrared Spectroscopy of Synovial Fluid Shows Accuracy as an Early Biomarker in an Equine Model of Traumatic Osteoarthritis.
Panizzi Luca, Vignes Matthieu, Dittmer Keren E et al. (2024) — Animals : an open access journal from MDPI
Cohort Study
Pharmacokinetics and pharmacodynamics of clodronate disodium evaluated in plasma, synovial fluid and urine.
Krueger Clarisa R, Mitchell Colin F, Leise Britta S et al. (2020) — Equine veterinary journal
Cohort Study
Cartilage-derived retinoic acid-sensitive protein in equine synovial fluid from healthy and diseased joints.
Berg L C, Lenz J, Kjelgaard-Hansen M et al. (2008) — Equine veterinary journal
Cohort Study
Influence of repeated arthrocentesis and exercise on synovial fluid concentrations of nitric oxide, prostaglandin E2 and glycosaminoglycans in healthy equine joints.
van den Boom R, van de Lest C H A, Bull S et al. (2005) — Equine veterinary journal
Cohort Study
Intra-articular triamcinolone acetonide improves lung function in horses with severe asthma.
Bessonnat A, Picotte K, Lavoie J P (2020) — Equine veterinary journal
Case Report
Plasma firocoxib concentrations after intra-articular injection of autologous conditioned serum prepared from firocoxib positive horses.
Ortved K F, Goodale M B, Ober C et al. (2017) — Veterinary journal (London, England : 1997)
Case Report
Characterization of mesenchymal stem cells derived from the equine synovial fluid and membrane.
Prado Aline Ambrogi Franco, Favaron Phelipe Oliveira, da Silva Luis Claudio Lopes Correia et al. (2015) — BMC veterinary research
Case Report
Advancements in Subchondral Bone Biomechanics: Insights from Computed Tomography and Micro-Computed Tomography Imaging in Equine Models.
Malekipour, Whitton, Lee (2024) — Current osteoporosis reports
Expert Opinion
Current use of biologic therapies for musculoskeletal disease: A survey of board-certified equine specialists.
Knott Lindsay E, Fonseca-Martinez B Alexander, O'Connor Annette M et al. (2022) — Veterinary surgery : VS
Expert Opinion
Gene therapy approaches for equine osteoarthritis.
Thampi Parvathy, Samulski R Jude, Grieger Joshua C et al. (2022) — Frontiers in veterinary science
Expert Opinion
Non-steroidal anti-inflammatory drugs in equine orthopaedics.
Jacobs Carrie C, Schnabel Lauren V, McIlwraith C Wayne et al. (2022) — Equine veterinary journal
Expert Opinion
Undenatured Type II Collagen (UC-II) in Joint Health and Disease: A Review on the Current Knowledge of Companion Animals.
Gencoglu Hasan, Orhan Cemal, Sahin Emre et al. (2020) — Animals : an open access journal from MDPI
Expert Opinion
Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory.
Gupta Ramesh C, Lall Rajiv, Srivastava Ajay et al. (2019) — Frontiers in veterinary science
Expert Opinion
Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know.
Bogers Sophie Helen (2018) — Frontiers in veterinary science
Expert Opinion
The Importance of Subchondral Bone in the Pathophysiology of Osteoarthritis.
Stewart Holly L, Kawcak Christopher E (2018) — Frontiers in veterinary science
Expert Opinion
Recent advances in articular cartilage evaluation using computed tomography and magnetic resonance imaging.
Nelson B B, Kawcak C E, Barrett M F et al. (2018) — Equine veterinary journal
Expert Opinion
Characterisation and intracellular labelling of mesenchymal stromal cells derived from synovial fluid of horses and sheep.
Burk J, Glauche S M, Brehm W et al. (2017) — Veterinary journal (London, England : 1997)
Expert Opinion
Cell-based cartilage repair strategies in the horse.
Ortved Kyla F, Nixon Alan J (2016) — Veterinary journal (London, England : 1997)
Expert Opinion
mRNA expression of genes involved in inflammation and haemostasis in equine fibroblast-like synoviocytes following exposure to lipopolysaccharide, fibrinogen and thrombin.
Andreassen Stine Mandrup, Berg Lise C, Nielsen Søren Saxmose et al. (2015) — BMC veterinary research
Expert Opinion
Show 10 more references
Animal Models of Osteoarthritis: Comparisons and Key Considerations.
McCoy A M (2015) — Veterinary pathology
Expert Opinion
Effect of hoof orientation and ballast on acceleration and vibration in the hoof and distal forelimb following simulated impacts ex vivo.
McCarty C A, Thomason J J, Gordon K et al. (2015) — Equine veterinary journal
Expert Opinion
Effect of hoof angle on joint contact area in the equine metacarpophalangeal joint following simulated impact loading ex vivo.
McCarty C A, Thomason J J, Gordon K et al. (2015) — Equine veterinary journal
Expert Opinion
The horse as a model of naturally occurring osteoarthritis
McIlwraith C. W., Frisbie D. D., Kawcak C. E. (2012) — Bone & Joint Research
Expert Opinion
Comparisons of computed tomography, contrast-enhanced computed tomography and standing low-field magnetic resonance imaging in horses with lameness localised to the foot. Part 2: Lesion identification.
Vallance S A, Bell R J W, Spriet M et al. (2012) — Equine veterinary journal
Expert Opinion
Synovial fluid chondroitin sulphate indicates abnormal joint metabolism in asymptomatic osteochondritic horses.
Machado T S L, Correia da Silva L C L, Baccarin R Y A et al. (2012) — Equine veterinary journal
Expert Opinion
Effects of glucosamine hydrochloride and chondroitin sulphate, alone and in combination, on normal and interleukin-1 conditioned equine articular cartilage explant metabolism.
Dechant J E, Baxter G M, Frisbie D D et al. (2005) — Equine veterinary journal
Expert Opinion
Accuracy of diagnostic arthroscopy for the assessment of cartilage damage in the equine metacarpophalangeal joint.
Brommer H, Rijkenhuizen A B M, Brama P A J et al. (2004) — Equine veterinary journal
Expert Opinion
Dynamic compressive strain inhibits nitric oxide synthesis by equine chondrocytes isolated from different areas of the cartilage surface.
Wiseman M, Henson F, Lee D A et al. (2003) — Equine veterinary journal
Thesis
Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro.
Dechant J E, Baxter G M, Frisbie D D et al. (2003) — Equine veterinary journal
Thesis